- AbbVie Inc ABBV has announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating Imbruvica (ibrutinib) combined with Venclexta/Venclyxto (venetoclax) for untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% among patients without del(17p), 70 years old or younger, and 27.9 months of follow-up.
- This rate was higher than the 37% minimum meaningful rate study assumption.
- The CR rate was consistent across all patients in the study, including high-risk CLL patient groups.
- Furthermore, 24-month progression-free survival (PFS) and overall survival (OS) were 95% and 98%, respectively.
- Undetectable minimal residual disease was achieved in 77% of patients in peripheral blood and 60% of patients in the bone marrow.
- The most common grade 3/4 adverse effects were neutropenia (33%), hypertension (6%), and neutrophil count decreased (5%).
- Adverse events led to the discontinuation of ibrutinib in 4% and venetoclax in 2% of patients.
- The safety profile of the combination was generally consistent with known AEs for each agent, and no new safety signals were identified.
- Price Action: ABBV shares are up 1.01% at $113.50 during the market session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.